

Attorney Docket No.: 2891-1-001PCT/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Benoit Chabot et al.

SERIAL NO.: 10/524,359

EXAMINER: Unassigned

DATE FILED: February 14, 2005

ART UNIT: Unassigned

FOR: METHODS TO REPROGRAM SPLICE SITE SELECTION IN PRE-MESSENGER RNAs

EXPRESS MAIL NO: EV 652397782 US

DATE OF DEPOSIT: SEPTEMBER 14, 2005

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References **CE** through **CZ** listed on the attached Supplemental Form PTO-1449. (Note: the reference listed as CE was previously included on the IDS filed with the application on February 14, 2005 as just an ABSTRACT; the supplemental IDS now includes a full copy of the article). No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,



DAVID A. JACKSON
Attorney for Applicants
Registration No. 26,742

KLAUBER & JACKSON LLC
411 Hackensack Avenue, 4th Floor
Hackensack, New Jersey 07601
(201) 487-5800

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	2891-1-001PCT/US
		SERIAL NO.	10/524,359
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary) SUPPLEMENTAL		APPLICANT	Benoit Chabot et al.
		FILING DATE	February 14, 2005
		GROUP	Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB-CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CE	Lacerra G, et al, Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients, 2000, FULL ARTICLE , Pgs. 9591-9596. <u>(Note: On IDS filed 2-14-05 we included an ABSTRACT ONLY for this article)</u>
CH	VILLEMAIRE et al., Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides, J. Biol. Chem., Vol. 278, No. 5050031-50039 (2003).
CI	NASIM et al., High-affinity hnRNP AI binding sites and duplex-forming inverted repeats have similar effects on 5' splice site selection in support of a common looping out and repression mechanism, RNA, V o l . 8:1078-I 079 (2002)
CJ	GOYENVALLE et al., Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping, Science, Vol. 306:1796-I 799 (2004).
CK	DOMINSKY et al., Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides, Proc. Natl. Acad. Sci. USA, Vol. 90:8673-8677 (1993).
CL	SIERAKOWSKA et al., Repair of thalassemic human R-globin mRNA in mammalian cells by antisense oligonucleotides, Proc. Natl. Acad. Sci. USA, Vol. 93:12840-12844 (1996).
CM	FRIEDMAN et al., Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides, J. Biol. Chem., Vol. 274, No. 51:36193-36199 (1999).

EXAMINER:

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	2891-1-001PCT/US
		SERIAL NO.	10/524,359
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	Benoit Chabot et al.
		FILING DATE	February 14, 2005
		GROUP	Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB-CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CN	SUTER et al., Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human β-thalassemic mutations, Hum. Mol. Gen., Vol. 8, No.13:2415-2423 (1999).	
CO	SIERAKOWSKA et al., Sensitivity of splice sites to antisense oligonucleotides in vivo, RNA, Vol. 5:369-377 (1999).	
CP	KARRAS et al., Peptide nucleic acids are potent modulators of endogenous Pre-mRNA splicing of the murine interleukin receptor-α chain, Biochem., Vol. 40:7853-7859 (2001).	
CQ	SAZANI et al., Nuclear antisense effects of neutral, anionic and cationic and cationic oligonucleotide analogs, Nuci. Acid Res., Vol. 29, No. 19:3965-3974 (2001).	
CR	DOMINSKY et al., identification and characterization by antisense oligonucleotides of exon and intron CM sequences required for splicing, Mol. and Cell. Biol., Vol. 14, No. 11:7445-7454 (1994).	
CS	MERCATANTE et al., Modification of alternative splicing pathways as a potential approach to chemotherapy, Pharmac. and Therap., Vol. 85237-243 (2000).	
CT	WILTON et al., Specific removal of the non-sense mutation from the mdx dystrophin mRNA using antisense oligonucleotides, Neuromusc. Dis., Vol. 9:330-338 (1999).	

EXAMINER:

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	2891-1-001PCT/US
		SERIAL NO.	10/524,359
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	Benoit Chabot et al.
		FILING DATE	February 14, 2005
		GROUP	Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB-CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CU	GORMAN et al., Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs, Proc. Nati. Acad. Sci. USA, Vol. 95:4929-4934 (1998).		
CV	SUTER et al., Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human β-thalassemic mutations, Hum. Mol. Gen., Vol. 8, No. 13:2415-2423 (1999).		
CW	SAZANI et al., Systemically delivered antisense oligomers upregulate gene expression in mouse tissues, Nature Biotech., Vol. 20: 1228-1 233 (2002).		
CX	SAZANI et al., Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing, J. Clin. Invest., Vol. 112, No. 4:481-486 (2003).		
CY	MERCATANTE et al., Modification of alternative splicing of bcl-x pre-mRNA in prostate and breast cancer cells, J. Biol. Chem., Vol. 276, No. 19:16411-16417 (2001).		
CZ	MERCATANTE et al., Cellular response to an antisense-mediated shift of bcl-x pre-mRNA splicing and antineoplastic agents, J. Biol. Chem., Vol. 277, No. 51:49374-49382 (2002).		

EXAMINER: _____ DATE CONSIDERED: _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.